CVRx Inc., a Minneapolis, MN-based medical device company, closed on an additional $12m in Series F financing.
Backers in the round, which brought the total amount raised by the company to date to $42m, included Ysios Capital, DaVita HealthCare Partners and others. In conjunction with the funding, Josep Sanfeliu, general partner of Ysios Capital, joined CVRx’ board of directors.
The company plans to use the capital to advance its clinical trials and expanding its international commercial activities.
Founded in 2001 and led by Nadim Yared, President and Chief Executive Officer, and Robert Kieval, Executive Vice President and Chief Technology Officer, CVRx has developed Barostim neo™, a novel medical device system designed to treat hypertension and heart failure.
Barostim neo received CE marking for the treatment of hypertension in Europe. It is under clinical evaluation for the treatment of heart failure in Europe and the United States and under clinical evaluation for the treatment of hypertension in the United States.